These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21136214)

  • 21. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
    Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
    J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.
    Xie Z; Chen EC; Stahl M; Zeidan AM
    Blood Rev; 2023 May; 59():101033. PubMed ID: 36357283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myelodysplastic syndromes].
    Solary E; Fontenay M
    Rev Prat; 2010 Dec; 60(10):1408-9, 1412. PubMed ID: 21425540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes.
    Gardikas N; Vikentiou M; Konsta E; Kontos CK; Papageorgiou SG; Spathis A; Bazani E; Bouchla A; Kapsimali V; Psarra K; Foukas P; Dimitriadis G; Pappa V
    Cytometry B Clin Cytom; 2019 Jan; 96(1):73-82. PubMed ID: 30334347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Myelodysplastic syndromes].
    Thol F; Heuser M; Ganser A
    Internist (Berl); 2015 Apr; 56(4):364-73. PubMed ID: 25700647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.
    Horiike S; Kita-Sasai Y; Nakao M; Taniwaki M
    Leuk Lymphoma; 2003 Jun; 44(6):915-22. PubMed ID: 12854888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
    Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
    Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The International Prognostic Scoring System for primary myelodysplastic syndrome].
    Sisková M; Dohnalová A; Neuwirtová R; Pĕnicková J; Karban J; Cmunt E
    Sb Lek; 2002; 103(3):333-8. PubMed ID: 12688177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
    Bektaş Ö; Üner A; Eliaçık E; Uz B; Işık A; Etgül S; Bozkurt S; Haznedaroğlu İC; Göker H; Sayınalp N; Aksu S; Demiroğlu H; Özcebe Oİ; Büyükaşık Y
    Turk J Haematol; 2016 Jun; 33(2):119-26. PubMed ID: 26376664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
    Kantarjian H; O'Brien S; Ravandi F; Cortes J; Shan J; Bennett JM; List A; Fenaux P; Sanz G; Issa JP; Freireich EJ; Garcia-Manero G
    Cancer; 2008 Sep; 113(6):1351-61. PubMed ID: 18618511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes.
    Creignou M; Bernard E; Gasparini A; Tranberg A; Todisco G; Moura PL; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Elena C; Ferrari J; Gallì A; Pozzi S; Malcovati L; Edgren G; Crowther MJ; Jädersten M; Papaemmanuil E; Hellström-Lindberg E
    J Intern Med; 2024 Jul; 296(1):53-67. PubMed ID: 38654517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.
    Greenberg PL
    J Natl Compr Canc Netw; 2013 Jul; 11(7):877-84; quiz 885. PubMed ID: 23847221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and genetic predictors of prognosis in myelodysplastic syndromes.
    Bejar R
    Haematologica; 2014 Jun; 99(6):956-64. PubMed ID: 24881041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revised international prognostic scoring system for myelodysplastic syndromes.
    Greenberg PL; Tuechler H; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Malcovati L; Cazzola M; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres M; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D
    Blood; 2012 Sep; 120(12):2454-65. PubMed ID: 22740453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Myelodysplastic syndromes--an overview for the practitioner].
    Solenthaler M; Tobler A
    Ther Umsch; 2004 Feb; 61(2):117-24. PubMed ID: 15018394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Markers of Myelodysplastic Syndromes.
    Veryaskina YA; Titov SE; Kovynev IB; Pospelova TI; Zhimulev IF
    Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
    Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
    Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.